- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Gastric or gastroesophageal junction (G/GOJ) cancer
- Meeting Date: May 2025
- Public Summary Document (PSD) May 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) May 2025 PBAC Meeting - (Word)
Trastuzumab Deruxtecan – May 2025
Trastuzumab Deruxtecan: Powder for I.V. infusion 100 mg; Enhertu®
Last updated
9 May 2025